Monrovia Post Acute: Parkinson's Tracking Failure, CA

DUARTE, CA - A California nursing home administered Parkinson's medication to a resident for months without properly documenting the diagnosis in medical records, creating potential safety risks during a critical medication trial period.

Missing Diagnosis Creates Documentation Gap

Monrovia Post Acute faced citations during a May 2025 inspection after regulators discovered that a resident receiving Sinemet, a medication for Parkinson's disease, did not have the diagnosis properly recorded in their comprehensive assessment records. The resident had been prescribed the medication since January 2025 following a neurologist consultation, yet the facility's Minimum Data Set (MDS) assessment failed to include Parkinson's disease under the neurological conditions section.

The 84-year-old resident, who had multiple complex medical conditions including dementia, diabetes, and heart irregularities, was observed by inspectors to have noticeable tremors in both upper extremities - a characteristic symptom of Parkinson's disease. Despite these visible symptoms and an active prescription for Sinemet, the facility's April 2025 assessment omitted the neurological diagnosis entirely.

Licensed Vocational Nurse 3, when questioned by inspectors, acknowledged the error, stating "the diagnosis was not coded in Resident 2's MDS dated [DATE], and the MDS was inaccurate." The nurse emphasized that "the correct resident's diagnosis was important; otherwise, Resident 2 could be taking medication that may result in an adverse medication event."

Critical Medication Monitoring Gaps

The documentation failure occurred during a particularly vulnerable period for the resident. According to the neurologist's consultation notes from January 2025, the resident was started on what medical professionals call a "Levodopa trial" - a diagnostic treatment approach used to determine if a patient's symptoms respond to Parkinson's medication.

The prescribing neurologist had specifically warned facility staff about potential complications, noting that "Levodopa may worsen or precipitate behavior disturbances" and instructing staff to "contact me right away if there are any concerns for adverse reactions." Despite these clear monitoring instructions, the facility never followed up with the neurologist after initiating the medication.

When contacted by inspectors, the neurologist confirmed he had only seen the resident one time and there was no follow-up by the facility, even though he indicated "follow-up on Resident 2's Levodopa trial could be done in a day or two after Resident 2 started taking Sinemet."

Medical Risks of Inadequate Monitoring

Sinemet contains levodopa and carbidopa, medications that require careful monitoring due to their potential for significant side effects. Medical protocols emphasize the importance of regular assessment during the initial treatment period, particularly for elderly patients with multiple medical conditions and cognitive impairment.

The medication can cause dyskinesia - abnormal, involuntary movements that can significantly impact a patient's quality of life and safety. Other potential adverse effects include confusion, hallucinations, and behavioral changes, which can be particularly problematic for residents with existing dementia.

For patients with multiple medical conditions like this resident, who had diabetes, heart rhythm disorders, and blood pressure issues, medication interactions and side effects require heightened vigilance. The combination of cognitive impairment and complex medical needs makes accurate diagnosis documentation essential for safe medication management.